Cancer And The Immune System: FDA Panel’s Approval Of Pioneering T-Cell Therapy

Print icon

The availability of a pioneering T-cell therapy, the first treatment that genetically alters a patient’s cells, moved one step closer recently with FDA approval.

The T-cell therapy, created at the University of Pennsylvania and licensed to the pharmaceutical company Novartis, removes immune cells from the patient’s bloodstream, genetically reengineering them to recognize and kill cancer, multiplying the immune cells and infusing them into the patient’s body.

The therapy was approved for patients ages 3 to 25 with B-cell acute lymphoblastic leukemia that has relapsed or has not responded to standard treatments. The FDA is expected to announce its decision on making the protocol available in the next few months.

“This is an exciting advance that has, and will, save lives,” says Peter Yu, physician-in-chief of the Hartford HealthCare Cancer Institute. “It has been developed over the last four to five years and is part of the growing story of immunotherapy and cancer. We have learned that the immune system has so many weapons at its disposal.”

Yu expects the FDA will make the immunotherapy available at a limited number of sites across the United States, including the Memorial Sloan Kettering Cancer Center in New York, a Hartford HealthCare partner.

“Our doctors will work to identifyHartford HealthCare patients who might benefit from the treatments and facilitate accessing treatment at MSK if appropriate,|” he says.

Besides this new T-cell therapy, which will be marketed as Kymriah, other research studies into perfecting and implementing genetic therapy for cancer patients are ongoing, including a Memorial Sloan Kettering study that Hartford HealthCare patients can join here in Connecticut at the HHC Cancer Institute.

While Dr. Yu says “for the right patient, this treatment is going to be life-changing and life-saving,” the anticipated initial approval of T-cell therapy will be for use in patients whose disease has not been controlled by earlier treatments with conventional therapies, by which time the patient is often weaker and the disease harder to treat.

“They’re looking at the timing of its use,” he says of the T-cell therapy, “whether we can give it sooner so the patients have fewer side effects and it might be more effective.”

Earlier use may also help patients avoid such difficult treatments as bone marrow transplants.

Other studies are investigating the application of this new treatment to cancers such as leukemia not borne in the bloodstream. Approximately 90 percent of patients have so-called “solid tumors” of the lungs, ovaries or other organs. Dr. Yu says immunotherapy with reengineered T-cells may not be as effective in these cases because they may be less able to kill tumors when required to leave the bloodstream and locate their targets in other parts of the body.

“The question is, Can these re-engineered cells get into solid tumors?” says Dr. Yu. “Perhaps there are other kinds of immune cells that may be better subjects for genetic engineering to accomplish this.”

But in some cases, T-cell therapy may be more effective than chemotherapy. The treatment holds promise for use against glioblastoma, the aggressive type of brain cancer afflicting Sen. John McCain, says Dr. Yu. The brain typically has been a challenge for standard cancer treatments, but T-cell therapy may prove effective because immune cells are better able to enter the brain than chemotherapy drugs, which need to get through the blood-brain barrier that protects the brain from many drugs.

Meanwhile, some area leukemia patients at the Cancer Institute locations may soon be referred to Memorial Sloan Kettering to access the advanced, newly-approved therapy.

“T-cell therapy represents a continuation of the renaissance of blood and cancer care,” says Dr. Jeffrey Gordon, an oncologist with Hartford HealthCare Medical Group Oncology. “For my patients who may need this type of therapy, the relationship that Hartford HealthCare has with the Memorial Sloan Kettering Cancer Center opens up a door of opportunity for them. They can get the most up-to-date, technologically advanced therapy while still being connected to their care close to home.”

 

For more information on the Hartford HealthCare Cancer Institute, click here.

 


What's New

Cancer cells.

Dr. Wylie Hosmer: Weaponizing Your Immune System Against Cancer

By Dr. Wylie D. Hosmer The three most terrifying words in the English language may be: “You have cancer.” But exciting advances in research have uncovered more powerful treatment options, using the patient’s immune system, to target and attack cancer cells. More research is needed, but this treatment known as...


Child Car Seat Safety: Installation is Key

Did you know that accidents – including car accidents – are the leading cause of children’s deaths? Child safety seats can reduce death by as much as 71 percent and prevent injury but only if they are used correctly, according to Safe Kids Connecticut. Connecticut law requires that all children...

Woman taking out trash.

Is Taking Out The Trash Any Way To Live Longer? (Really?)

Thanks to fitness-tracker accelerometers, researchers have learned more precisely the amount of physical activity it takes to live a longer, fitter life. Surprisingly, not much. Three studies that used accelerometers to measure participants’ activity  concluded in recent months that even the lightest regular physical activity — making a bed, taking...

IV bags.

How Hurricane Maria Caused Nationwide IV Bag Shortage

With a nationwide shortage of intravenous bags, clinical pharmacies across Hartford Healthcare are working to ensure patient care isn’t interrupted. The Wall Street Journal reported that the shortage began in September after a group of IV bag manufacturing plants in Puerto Rico lost power because of Hurricane Maria. The shortage...

Man with flu.

The ‘Man Flu’: A Severe Case or Severe Wimpiness?

When it comes to complaining about flu and other upper-respiratory infection symptoms, men might not be wimps after all.  Maybe. A new study by researchers at Memorial University of Newfoundland in Canada found that “man flu” — a term often used by women who think that men complain more about...